Quantifying the Effect of Vpu on the Promotion of HIV-1 Replication in the Humanized Mouse Model

Overview

Journal Retrovirology

Publisher Biomed Central

Specialty Microbiology

Date 2016 Apr 19

PMID 27086687

Citations 11

Authors

Hiroki Ikeda

Shinji Nakaoka

Rob J De Boer

Satoru Morita

Naoko Misawa

Yoshio Koyanagi

Kazuyuki Aihara

Kei Sato

Shingo Iwami

Affiliations

Soon will be listed here.

Abstract

Background: Tetherin is an intrinsic anti-viral factor impairing the release of nascent HIV-1 particles from infected cells. Vpu, an HIV-1 accessory protein, antagonizes the anti-viral action of tetherin. Although previous studies using in vitro cell culture systems have revealed the molecular mechanisms of the anti-viral action of tetherin and the antagonizing action of Vpu against tetherin, it still remains unclear how Vpu affects the kinetics of HIV-1 replication in vivo.

Results: To quantitatively assess the role of Vpu in viral replication in vivo, we analyzed time courses of experimental data with viral load and target cell levels in the peripheral blood of humanized mice infected with wild-type and vpu-deficient HIV-1. Our recently developed mathematical model describes the acute phase of this infection reasonably, and allowed us to estimate several parameters characterizing HIV-1 infection in mice. Using a technique of Bayesian parameter estimation, we estimate distributions of the basic reproduction number of wild-type and vpu-deficient HIV-1. This reveals that Vpu markedly increases the rate of viral replication in vivo.

Conclusions: Combining experiments with mathematical modeling, we provide an estimate for the contribution of Vpu to viral replication in humanized mice.

Citing Articles

Estimation of timing of infection from longitudinal SARS-CoV-2 viral load data: mathematical modelling study.

Ejima K, Kim K, Bento A, Iwanami S, Fujita Y, Aihara K BMC Infect Dis. 2022; 22(1):656.

PMID: 35902832 PMC: 9331019. DOI: 10.1186/s12879-022-07646-2.

Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection.

Kim K, Iwanami S, Oda T, Fujita Y, Kuba K, Miyazaki T Life Sci Alliance. 2021; 4(10).

PMID: 34344719 PMC: 8340032. DOI: 10.26508/lsa.202101049.

Revisiting the guidelines for ending isolation for COVID-19 patients.

Jeong Y, Ejima K, Kim K, Iwanami S, Bento A, Fujita Y Elife. 2021; 10.

PMID: 34311842 PMC: 8315804. DOI: 10.7554/eLife.69340.

Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study.

Iwanami S, Ejima K, Kim K, Noshita K, Fujita Y, Miyazaki T PLoS Med. 2021; 18(7):e1003660.

PMID: 34228712 PMC: 8259968. DOI: 10.1371/journal.pmed.1003660.

Dynamical characterization of antiviral effects in COVID-19.

Abuin P, Anderson A, Ferramosca A, Hernandez-Vargas E, Gonzalez A Annu Rev Control. 2021; 52:587-601.

PMID: 34093069 PMC: 8162791. DOI: 10.1016/j.arcontrol.2021.05.001.

References

Stafford M, Corey L, Cao Y, Daar E, Ho D, Perelson A . Modeling plasma virus concentration during primary HIV infection. J Theor Biol. 2000; 203(3):285-301. DOI: 10.1006/jtbi.2000.1076. View

Kirchhoff F . Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe. 2010; 8(1):55-67. DOI: 10.1016/j.chom.2010.06.004. View

Perelson A . Modelling viral and immune system dynamics. Nat Rev Immunol. 2002; 2(1):28-36. DOI: 10.1038/nri700. View

Schubert U, Clouse K, Strebel K . Augmentation of virus secretion by the human immunodeficiency virus type 1 Vpu protein is cell type independent and occurs in cultured human primary macrophages and lymphocytes. J Virol. 1995; 69(12):7699-711. PMC: 189711. DOI: 10.1128/JVI.69.12.7699-7711.1995. View

Sauter D, Schindler M, Specht A, Landford W, Munch J, Kim K . Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe. 2009; 6(5):409-21. PMC: 2779047. DOI: 10.1016/j.chom.2009.10.004. View

Neil S, Zang T, Bieniasz P . Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature. 2008; 451(7177):425-30. DOI: 10.1038/nature06553. View

Iwami S, Sato K, Morita S, Inaba H, Kobayashi T, Takeuchi J . Pandemic HIV-1 Vpu overcomes intrinsic herd immunity mediated by tetherin. Sci Rep. 2015; 5:12256. PMC: 4505337. DOI: 10.1038/srep12256. View

Little S, McLean A, Spina C, Richman D, Havlir D . Viral dynamics of acute HIV-1 infection. J Exp Med. 1999; 190(6):841-50. PMC: 2195636. DOI: 10.1084/jem.190.6.841. View

Schubert U, Anton L, Bacik I, Cox J, Bour S, Bennink J . CD4 glycoprotein degradation induced by human immunodeficiency virus type 1 Vpu protein requires the function of proteasomes and the ubiquitin-conjugating pathway. J Virol. 1998; 72(3):2280-8. PMC: 109526. DOI: 10.1128/JVI.72.3.2280-2288.1998. View

10.

Ribeiro R, Qin L, Chavez L, Li D, Self S, Perelson A . Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J Virol. 2010; 84(12):6096-102. PMC: 2876646. DOI: 10.1128/JVI.00127-10. View

11.

Levesque K, Finzi A, Binette J, Cohen E . Role of CD4 receptor down-regulation during HIV-1 infection. Curr HIV Res. 2004; 2(1):51-9. DOI: 10.2174/1570162043485086. View

12.

Claiborne D, Prince J, Scully E, Macharia G, Micci L, Lawson B . Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4+ T cells, and disease progression. Proc Natl Acad Sci U S A. 2015; 112(12):E1480-9. PMC: 4378387. DOI: 10.1073/pnas.1421607112. View

13.

Sato K, Izumi T, Misawa N, Kobayashi T, Yamashita Y, Ohmichi M . Remarkable lethal G-to-A mutations in vif-proficient HIV-1 provirus by individual APOBEC3 proteins in humanized mice. J Virol. 2010; 84(18):9546-56. PMC: 2937654. DOI: 10.1128/JVI.00823-10. View

14.

Lorenzo-Redondo R, Fryer H, Bedford T, Kim E, Archer J, Kosakovsky Pond S . Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature. 2016; 530(7588):51-56. PMC: 4865637. DOI: 10.1038/nature16933. View

15.

Sato K, Misawa N, Iwami S, Satou Y, Matsuoka M, Ishizaka Y . HIV-1 Vpr accelerates viral replication during acute infection by exploitation of proliferating CD4+ T cells in vivo. PLoS Pathog. 2013; 9(12):e1003812. PMC: 3855622. DOI: 10.1371/journal.ppat.1003812. View

16.

Sato K, Misawa N, Fukuhara M, Iwami S, An D, Ito M . Vpu augments the initial burst phase of HIV-1 propagation and downregulates BST2 and CD4 in humanized mice. J Virol. 2012; 86(9):5000-13. PMC: 3347374. DOI: 10.1128/JVI.07062-11. View

17.

Nie C, Sato K, Misawa N, Kitayama H, Fujino H, Hiramatsu H . Selective infection of CD4+ effector memory T lymphocytes leads to preferential depletion of memory T lymphocytes in R5 HIV-1-infected humanized NOD/SCID/IL-2Rgammanull mice. Virology. 2009; 394(1):64-72. DOI: 10.1016/j.virol.2009.08.011. View

18.

Sato K, Gee P, Koyanagi Y . Vpu and BST2: Still Not There Yet?. Front Microbiol. 2012; 3:131. PMC: 3321438. DOI: 10.3389/fmicb.2012.00131. View

19.

Margottin F, Bour S, Durand H, Selig L, Benichou S, Richard V . A novel human WD protein, h-beta TrCp, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol Cell. 1998; 1(4):565-74. DOI: 10.1016/s1097-2765(00)80056-8. View

20.

Bour S, Schubert U, Strebel K . The human immunodeficiency virus type 1 Vpu protein specifically binds to the cytoplasmic domain of CD4: implications for the mechanism of degradation. J Virol. 1995; 69(3):1510-20. PMC: 188742. DOI: 10.1128/JVI.69.3.1510-1520.1995. View